The board of directors of SSY Group Limited announced that the Group's Norepinephrine bitartrate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Norepinephrine bitartrate is an adrenergic receptors agonist, which is mainly used clinically in anti-shock by causing extreme contraction of blood vessels to increase blood pressure and coronary blood flow as well as by strengthening myocardial contraction and increasing cardiac output.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.71 HKD | -0.84% | +0.21% | -4.66% |
May. 28 | SSY Obtains China Approval for Additional Specification, Generic Status of Metabolic Acidosis Drug | MT |
May. 28 | SSY Group Limited Announces Update on Product Development | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.66% | 1.81B | |
+39.22% | 727B | |
+30.57% | 592B | |
-7.85% | 347B | |
+15.48% | 319B | |
-0.12% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.37% | 160B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market